Clinical Trial

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Study acronym: STELLAR-201
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Protocol Amendment History 4 changes
notable Trial sites expanded: 6 -> 12 locations 2026-07-14
notable Trial sites expanded: 3 -> 6 locations 2026-06-25
critical Recruitment opened 2026-05-28
notable Trial sites expanded: 0 -> 3 locations 2026-05-19
Trial Details
NCT Number NCT07428616
Lead Sponsor Exelixis
Conditions Meningioma
Enrollment 100 participants
Start Date 2026-05-21
Primary Completion 2028-02-29 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-27